Skip to content

PR-Web

Press releases worldwide

  • Home
  • Contact
  • Datenschutzerklärung
  • Legal notice

Author: Firma Eckert & Ziegler Strahlen- und Medizintechnik

Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225

Posted on 6. July 2022 by Firma Eckert & Ziegler Strahlen- und Medizintechnik Posted in General Tagged alpha, beta, cells, clinical, cmc, discovery, eckert, gamma, market, new, packaging, production, treatment, trillium, with

Eckert & Ziegler (ISIN DE0005659700, SDAX) has signed an agreement with the U.S. pharmaceutical company Ratio Therapeutics Inc. for the joint development and manufacture of innovative radiopharmaceutical products based on Lu-177 and Ac-225. The agreement covers the development of a […]

Read More

Eckert & Ziegler with Sales Growth in the First Quarter of 2022

Posted on 12. May 202213. May 2022 by Firma Eckert & Ziegler Strahlen- und Medizintechnik Posted in General Tagged board, company, eckert, energy, figure, financial, forecast, medical, oil, report, revenue, tecnonuclear, tumour, with, ziegler

Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 13% to EUR 49.9 million in the first quarter of 2022. The net profit of EUR 6.7 million or EUR 0.32 per share was below the […]

Read More

Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Alpha Radioisotopes

Posted on 11. May 202212. May 2022 by Firma Eckert & Ziegler Strahlen- und Medizintechnik Posted in General Tagged actinium, alpha, cancer, cells, clinical, eckert, energy, market, micro, production, prostate, radium, research, ujf, with

Eckert & Ziegler AG (ISIN DE0005659700, TecDAX), a specialist in medical radioisotopes, has entered into a long-term cooperation agreement with the Nuclear Physics Institute of the Czech Academy of Sciences (Ústav jaderné fyziky, UJF) to produce the alpha emitter Actinium-225. […]

Read More

Eckert & Ziegler: Radboud University Medical Center Netherlands to Image First Patient with PENTIXAFOR

Posted on 8. April 20228. April 2022 by Firma Eckert & Ziegler Strahlen- und Medizintechnik Posted in General Tagged adrenal, aldosteronism, bah, cancer, castus, cxcr4, gold, patients, pentixafor, pentixapharm, pet, rumc, tumour, vein, with

Radboud University Medical Center (RUMC) in Nijmegen, one of the largest centres of excellence in the Netherlands for adrenal diseases, treated the first patient with primary aldosteronism with the Ga-68-based diagnostic PENTIXAFOR as part of the CASTUS study. Developed by […]

Read More

Eckert & Ziegler with Record Results in FY 2021 and Positive Outlook

Posted on 30. March 2022 by Firma Eckert & Ziegler Strahlen- und Medizintechnik Posted in General Tagged bearing, board, company, dividend, eckert, financial, fiscal, forecast, medical, new, statements, supervisory, tumor, with, ziegler

Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) achieved sales of EUR 180.4 million in fiscal year 2021 (previous year: EUR 176.1 million). The consolidated net income for the year reached a new record level of EUR 34.5 […]

Read More

Eckert & Ziegler to Increase Dividend Proposal

Posted on 25. March 2022 by Firma Eckert & Ziegler Strahlen- und Medizintechnik Posted in General Tagged amounted, amp, bearing, board, dividend, eckert, exchange, financial, fiscal, forecast, payment, statements, supervisory, with, ziegler

Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) closed fiscal year 2021 with sales of 180.4 million EUR (previous year: 176.1 million EUR) and net income of 34.5 EUR (previous year: 22.9 million EUR). Earnings per share amounted to EUR 1.67 […]

Read More

Eckert & Ziegler to Supply Canadian Alpha-9 Theranostics with Lutetium-177 for Clinical Trials

Posted on 23. March 202223. March 2022 by Firma Eckert & Ziegler Strahlen- und Medizintechnik Posted in General Tagged alpha, beta, cancer, cells, clinical, drugs, eckert, lutetium, mines, nca, patients, production, therapy, treatment, with

Eckert & Ziegler (ISIN DE0005659700, TecDAX) has executed with the Canadian biotech company Alpha-9 Theranostics Inc. (Alpha-9) a clinical supply agreement for Eckert & Ziegler’s medical radioisotope Lutetium-177 (non-carrier-added 177Lu). The isotope will be used for the clinical development of […]

Read More

Eckert & Ziegler Extends Supply Agreement with Sirtex Medical to Chinese Market

Posted on 22. March 2022 by Firma Eckert & Ziegler Strahlen- und Medizintechnik Posted in General Tagged cancer, clinical, cmc, eckert, liver, market, new, packaging, production, radiotherapy, sirtex, strong, therapy, treatment, with

Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) and Sirtex Medical (Sirtex) have extended their long-term supply agreement for the use of yttrium-90 in Sirtex microspheres for the treatment of liver cancer to the Chinese market. The agreement guarantees EZAG a […]

Read More

Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176

Posted on 11. January 2022 by Firma Eckert & Ziegler Strahlen- und Medizintechnik Posted in General Tagged arm, bayer, cancer, clinical, eckert, ezr, lutetium, mines, nca, new, patients, production, prostate, telix, with

Eckert & Ziegler Radiopharma GmbH (EZR), the radiopharmaceutical production arm of Eckert & Ziegler, has signed a joint venture and exclusive long-term supply agreements for Ytterbium-176 with Atom Mines LLC, an innovative producer of enriched Ytterbium isotopes and a subsidiary […]

Read More

Eckert & Ziegler Acquires Argentinian SPECT Specialist

Posted on 3. January 2022 by Firma Eckert & Ziegler Strahlen- und Medizintechnik Posted in General Tagged cancer, eckert, financial, market, new, nuclear, patients, photon, power, production, research, revenues, spect, tecnonuclear, with

Eckert & Ziegler has acquired 100% of the shares of Argentinian nuclear medicine specialist Tecnonuclear S. A., a manufacturer of Technetium-99 generators and a portfolio of related biomolecules. These so-called “cold kits” function as vectors for the in-vivo delivery of […]

Read More

Posts navigation

Older posts
Newer posts

Copyright 2016. All rights reserved.


Back To Top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkRead more